quinacrine has been researched along with Cytokine Release Syndrome in 1 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Quinacrine (Qx) has been used since the 1930s as preventive antimalarial compound." | 2.72 | Quinacrine as a potential treatment for COVID-19 virus infection. ( Hernández Pando, R; Pérez de la Cruz, V; Pineda, B; Sotelo, J, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pineda, B | 1 |
| Pérez de la Cruz, V | 1 |
| Hernández Pando, R | 1 |
| Sotelo, J | 1 |
1 review available for quinacrine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Quinacrine as a potential treatment for COVID-19 virus infection.
Topics: Animals; Antiviral Agents; Cell Line; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; | 2021 |